Markets

Viridian Therapeutics To Present VRDN-008 Phase 1 Data And Outline FcRn Portfolio Development Plans On Monday, November 9, 2026, At 8:00 a.m. ET

Nov 6, 2026 · 04:02 PM ET· updated 26m ago

Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced it will

Why It Matters

Viridian will show early test results for a new medicine on Monday. When companies share real data, you can start to see if their science is working.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

VRDN29.51

+0.96 (+3.35%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.